Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice

Diabetes Mellitus Type 2 Clinical Trial

— FLORA  

Official title:

A Multicentre Randomised Open-Label Crossover 2-Period 2 Treatment Clinical Trial to Evaluate Effect of Dapagliflozin 10 mg Once Daily on the Quality of Life in Patients With Type 2 Diabetes

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02719132
• Other study ID #: D1690C00043
• Status: Withdrawn
• Phase: Phase 4
• First received: March 21, 2016
• Last updated: May 19, 2016
• Start date: July 2016
• Est. completion date: November 2017

Study information

• Verified date: May 2016
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: Russia: Ministry of Health of the Russian Federation
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomised, open-label, crossover, 2-period comparative phase IV study.

The primary objective is to compare the effect of dapagliflozin 10 mg once daily in combination with metformin at a daily dose of ≤1,500 mg vs. metformin monotherapy with dose titrated up to 2,500 mg/day on the overall quality of life, obesity-specific quality of life and treatment satisfaction in patients with type 2 diabetes.

Description:

The study will comprise the following phases: Screening, Treatment Period 1 and Treatment Period 2.

After screening examinations and assessments, all patients enrolled will be randomly assigned in equal proportion (1:1) to either study arm:

Arm 1:

• Patients will take dapagliflozin 10 mg in combination with metformin ≤ 1,500 mg (daily dose) for 24 weeks during Treatment Period 1

• Patients will be on metformin monotherapy with dose titrated up to 2,500 mg/day for further 24 weeks during Treatment Period 2

Arm 2 (the same treatment phases in reverse order):

• Patients will be on metformin monotherapy with dose titrated up to 2,500 mg/day for 24 weeks during Treatment Period 1

• Patients will take dapagliflozin 10 mg in combination with metformin ≤ 1,500 mg (daily dose) for further 24 weeks during Treatment Period 2 Following the randomisation procedure, patients will receive investigational products at each visit as scheduled by Treatment Period 1. After the Randomisation Visit (Visit 2), the patient should attend the study centre for Visits 3, 4, and 5 (Day 28, Day 86, and Day 168, respectively) for efficacy and safety assessments. At Visit 5 (Day 168), the patient will receive investigational products as required by Treatment Period 2. Further Visits 6, 7 and 8 will be scheduled on Day 196, Day 252, Day 336, respectively.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 2017
• Est. primary completion date: November 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

For inclusion in the study patients should fulfil ALL the criteria listed below:

1. A voluntary informed consent form for participation in the study signed by the patient prior to any study-specific procedures

2. Male and female patients of 18-74 years of age

3. Diagnosed type 2 diabetes

4. Therapy with metformin at a stable dose =1,500 mg/day for at least 8 weeks before enrolment

5. HbA1c >7.0% and =10% at the Screening Visit

6. C-peptide =1.0 ng/ml at the Screening Visit

7. Body mass index =45.0 kg/m² at the Screening Visit

8. For women of childbearing potential - use of reliable birth control methods

9. Ability to complete study-specific procedures

10. Ability to complete questionnaires

Exclusion Criteria:

1. Type 1 diabetes

2. Diabetic ketoacidosis at Screening

3. AST and/or ALT > 3 × upper limit of normal at Screening

4. Total serum bilirubin > 34.19 µmol/l at Screening

5. Decompensated diabetes mellitus (HbA1c >10% at Screening)

6. Patients with moderate to severe renal impairment (CrCl <60 ml/min or <60 ml/min/1.73 m2 at Screening) or terminal renal insufficiency

7. Severe concomitant diseases or severe cardiovascular, renal, hepatic, hematologic, endocrine, mental or rheumatic pathology

8. Malignancy within 5 years before enrolment

9. Acute (including viral and infectious) diseases within 1 month before the Screening Visit.

10. Development of severe acute diseases during the study which significantly affect the benefit/risk ratio for the subject or affecting study efficacy/safety assessment criteria

11. History of acute myocardial infarction or stroke within 6 months before the Screening Visit or during the study. Heart failure (NYHA III-IV)

12. Treatment with drugs affecting glucose homeostasis (e.g., systemic glucocorticosteroids) within 3 months before to the Screening Visit.

13. For women of childbearing potential - a positive pregnancy test or the patient is breast-feeding or planning pregnancy during the study

14. History of Hepatitis B and C or HIV

15. Individual hypersensitivity to any component of the investigational product (dapagliflozin)

16. Treatment with sodium-dependent glucose cotransporter inhibitors (SGLT2) has been administered within 3 months prior to enrolment or is planned during the study.

17. Loop diuretics have been administered for 3 months before the Screening Visit or are planned during the study.

18. Hereditary lactose intolerance, lactase deficiency and glucose-galactose malabsorption

19. The patient is unable to follow study procedures and attend the study centre for scheduled study visits or is going to relocate within the protocol-specific timelines

20. The patient is a subject of other studies within 3 months before enrolment

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus Type 2
• Diabetes Mellitus, Type 2

Intervention

Drug:
• Dapagliflozin
Dapagliflozin, 10 mg
• Metformin
Metformin, up to 2500 mg

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	ECG variables	ECG records including the following variables: heart rate (beats per minute), QT (msec), QTcB (msec), sinus heart rate (yes/no)	48 weeks	Yes
Other	number of episodes of hypoglycaemia and ketoacidosis	number of episodes of hypoglycaemia and ketoacidosis	48 weeks	Yes
Other	change in glomerular filtration rate	change in glomerular filtration rate compared to baseline at Screening	48 weeks	Yes
Other	laboratory values changes	laboratory values (ALT, AST, total bilirubin, and creatinine)	48 weeks	Yes
Primary	Composite endpoint including quality of life score	Change in the overall quality of life, obesity-specific quality of life and treatment satisfaction in the course of the therapy by the end of each 24-week treatment period compared to the quality of life, obesity-specific quality of life and treatment satisfaction at baseline.	48 weeks	No
Secondary	Change in HbA1c level	Change in HbA1c level will be assessed as mean change in the course of the treatment compared to baseline.	48 weeks	No
Secondary	Change in body weight	Change in body weight will be assessed as mean change in body weight, mean percentage change in body weight and mean change in body mass index compared to baseline and as proportion of patients with body weight decreased by =5% during the treatment phase.	48 weeks	No
Secondary	Change in waist circumference	Change in waist circumference will be assessed as mean change and mean percentage change in waist circumference during the treatment phase compared to baseline.	48 weeks	No
Secondary	Change in fasting plasma glucose	Change in fasting plasma glucose will be assessed as mean change in fasting plasma glucose during the treatment phase compared to baseline.	48 weeks	No
Secondary	Proportion of patients	Proportion of patients who achieved therapeutic glycaemic response (HbA1c =7%).	48 weeks	No